Zhenya Lindgardt Sells 9,406 Shares of Sera Prognostics, Inc. (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 9,406 shares of Sera Prognostics stock in a transaction that occurred on Thursday, May 8th. The shares were sold at an average price of $2.44, for a total value of $22,950.64. Following the completion of the transaction, the chief executive officer now owns 867,251 shares of the company’s stock, valued at approximately $2,116,092.44. The trade was a 1.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Sera Prognostics Trading Up 4.7%

Shares of Sera Prognostics stock opened at $2.22 on Monday. The stock has a market capitalization of $83.61 million, a price-to-earnings ratio of -2.24 and a beta of 0.99. Sera Prognostics, Inc. has a twelve month low of $2.10 and a twelve month high of $9.91. The business’s 50 day simple moving average is $3.48 and its 200-day simple moving average is $5.49.

Sera Prognostics (NASDAQ:SERA) last issued its earnings results on Wednesday, May 14th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.06 million. Sell-side analysts predict that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Institutional Trading of Sera Prognostics

Large investors have recently modified their holdings of the company. BNP Paribas Financial Markets bought a new position in Sera Prognostics in the 4th quarter worth about $28,000. XTX Topco Ltd bought a new stake in shares of Sera Prognostics during the first quarter valued at approximately $39,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Sera Prognostics during the fourth quarter worth approximately $93,000. Gotham Asset Management LLC bought a new position in Sera Prognostics in the 4th quarter worth approximately $96,000. Finally, Walleye Capital LLC acquired a new stake in Sera Prognostics in the 4th quarter valued at approximately $98,000. Institutional investors and hedge funds own 54.64% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.